Digital Content 
NEWS #PharmaBuzz
30 Jan 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/01/30/3229458/0/en/Johnson-Johnson-receives-CHMP-positive-opinion-for-AKEEGA-niraparib-and-abiraterone-acetate-dual-action-tablet-for-the-treatment-of-patients-with-metastatic-hormone-sensitive-prost.html
12 Dec 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/us-fda-approves-akeega-as-the-first-precision-therapy-for-brca2-mutated-metastatic-castration-sensitive-prostate-cancer-with-54-reduction-in-disease-progression-vs-standard-of-care-302640552.html
25 Aug 2025
// INDPHARMAPOST
https://www.indianpharmapost.com/news/gsk-forays-into-oncology-in-india-with-jemperli-and-zejula-17655
04 Jul 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/07/03/3109837/0/en/Johnson-Johnson-submits-application-to-the-European-Medicines-Agency-seeking-indication-extension-of-AKEEGA-niraparib-and-abiraterone-acetate-dual-action-tablet-for-the-treatment-o.html
03 Jun 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/06/03/3092969/0/en/Johnson-Johnson-s-AKEEGA-niraparib-and-abiraterone-acetate-dual-action-tablet-is-the-first-PARP-inhibitor-combo-to-show-improved-efficacy-in-patients-with-HRR-mutated-mHSPC-vs-curr.html
03 Jun 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/johnson--johnson-leads-with-first-parp-inhibitor-combo-to-improve-efficacy-in-patients-with-hrr-altered-mcspc-302471320.html
Share